NEXUS Aortic Arch Stent Graft System
Endospan , Ltd. · Decision date Sep 21, 2026
What did the FDA approve?
The FDA record P250033/S004, decided 21 September 2026, is a Normal 180 Day Track supplement to PMA P250033 for the NEXUS Aortic Arch Stent Graft System, sponsored by Endospan, Ltd. The supplement reason is listed as a labeling change covering indications, instructions, shelf life, or tradename, and the stated decision is approval for a three-year shelf life.
The identifier shows this supplement shares the base PMA number of the original approval, so it modifies that file rather than establishing a new approval of the whole system. The record does not specify what labeling text changed, whether the shelf-life approval reflects real-time or accelerated data, or any clinical evidence, and it is not independent proof of safety or effectiveness; the device's original scope is described only as an endovascular system for treatment of ascending aorta and aortic arch lesions.
FDA approval order statement
approval for a 3 year shelf-life for the NEXUS Aortic Arch Stent Graft System
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 21, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250033/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Endospan , Ltd.
- Product code
- SDZ
- Decision code
- APPR
- Decision date
- Sep 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions.
- Applicant
- Endospan , Ltd.
- Product code
- SDZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250033 · Original PMA
NEXUS Aortic Arch Stent Graft System
P250033/S001 · Related supplement
NEXUS Aortic Arch Stent Graft System
P250033/S004 received
Application receipt date recorded by FDA.
P250033/S002 · Related supplement
NEXUS Aortic Arch Stent Graft System
P250033/S004 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P250033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Endospan , Ltd. | PMA approval | Apr 2, 2026 | FDA | |
NEXUS Aortic Arch Stent Graft SystemP250033/S001 | Endospan , Ltd. | PMA supplement | May 20, 2026 | FDA |
NEXUS Aortic Arch Stent Graft SystemP250033/S002 | Endospan , Ltd. | PMA supplement | Jul 24, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endospan , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 105 Alta Meadows Rd., Alta, WY, 83414
Sources and methodology
- Original FDA record: P250033/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
